<DOC>
	<DOC>NCT00332163</DOC>
	<brief_summary>A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.</brief_summary>
	<brief_title>Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Exanthema</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Sunscreening Agents</mesh_term>
	<criteria>Patients with unresectable metastatic adenocarcinoma of the colon or rectum that cannot, in the opinion of the investigator, be cured by surgical resection at the time of randomization; Patients who have failed first line treatment containing fluoropyrimidine and oxaliplatin based chemotherapy with or without bevacizumab for mCRC. â€¢ Prior irinotecan use for the treatment of mCRC.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>STEPP</keyword>
	<keyword>STEP</keyword>
	<keyword>STEEP</keyword>
	<keyword>mCRC</keyword>
	<keyword>Skin Toxicities</keyword>
	<keyword>Skin Rash</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Anti-EGFr Skin Rash</keyword>
	<keyword>colon cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>rectal cancer</keyword>
</DOC>